FINNENCE ▪ THE WIRE FILE
THE WIRE · № 75643
News▲ Bullish
Racura Oncology Cleared to Escalate RC220 to 100 mg/m2 in Phase 1 HARNESS-1 Trial in EGFR-Mutant Non-Small Cell Lung Cancer
KINDNews
DIRECTION▲ Bullish
SOURCES1
ENTITIES2
STORY SIZESTANDALONE
FIRST SEEN
LAST UPDATE
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Clearing dose escalation without toxicities de-risks an early-stage oncology program, a modest positive for the biotech.
Early safety clearance supports trial progress
CATALYST TO WATCH
Next cohort data and dose escalation
MAIN RISK
Later safety or efficacy failure
FULL DISPATCH
The HARNESS-1 Safety Review Committee identified no dose-limiting toxicities or treatment-related safety concerns in either Cohort 1 patient during the safety observation period and has recommended the trial proceed to the next planned dose level of RC220 in combination with osimertinib....
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
AFFECTEDSPDR Biotech ETF · XBI
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare, XBI
REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 202026-10-12 11:05 UTC
REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 202026-10-12 11:05 UTC
→CORRELATIONshares Healthcare
Keenova Presents a New TERLIVAZ® (terlipressin) Exploratory Analysis at American College of Gastroenterology Annual Meeting2026-10-12 11:30 UTC
Keenova Presents a New TERLIVAZ® (terlipressin) Exploratory Analysis at American College of Gastroenterology Annual Meeting2026-10-12 11:30 UTC
→CORRELATIONshares Healthcare
Retension Pharmaceuticals exceeds target with $45M IPO2026-10-12 11:53 UTC
Retension Pharmaceuticals exceeds target with $45M IPO2026-10-12 11:53 UTC
→CORRELATIONshares Healthcare
Six-Month Pilot Study Demonstrates Improved Guideline Adherence Following Implementation of Standardized Cirrhosis Clinical Pathway2026-10-12 12:00 UTC
Six-Month Pilot Study Demonstrates Improved Guideline Adherence Following Implementation of Standardized Cirrhosis Clinical Pathway2026-10-12 12:00 UTC
→CORRELATIONshares Healthcare
POMDOCTOR LIMITED Highlights the Shift from Reactive Treatment to Predictive Healthcare2026-10-12 12:00 UTC
POMDOCTOR LIMITED Highlights the Shift from Reactive Treatment to Predictive Healthcare2026-10-12 12:00 UTC
→CORRELATIONshares Healthcare
Accord BioPharma Launches FILKRI™ (filgrastim-laha); Now Offers Both Long- and Short-Acting G-CSF Options2026-10-12 12:05 UTC
Accord BioPharma Launches FILKRI™ (filgrastim-laha); Now Offers Both Long- and Short-Acting G-CSF Options2026-10-12 12:05 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.